| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1347637 | Tetrahedron: Asymmetry | 2008 | 6 Pages |
The stereoselective synthesis of oxaziridines with three stereogenic centres is presented in this paper. The chirality is provided by asymmetric induction, and a possible mechanism for the induced stereoselectivity is also discussed. These small heterocycles undergo the [3+2] cycloaddition reaction with aryl ethenes to afford enantiomerically pure isoxazolidines of controlled configurations. This class of heterocycles is present in the structure of various compounds of biological and pharmacological interest, which can undergo further synthetic modifications.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
(−)-(1′S,2S,3S)-3-Phenyl-2-(1-phenylethyl)oxaziridineC15H15NOEe = 100%[α]D21.0=-61.1 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-3-Phenyl-2-(1-phenylethyl)oxaziridineC15H15NOEe = 100%[α]D21.0=+81.5 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-3-Phenyl-2-(1-phenylethyl)oxaziridineC15H15NOEe = 100%[α]D21.0=+60.2 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-3-Phenyl-2-(1-phenylethyl)oxaziridineC15H15NOEe = 100%[α]D21.0=-79.9 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-2-(1-Phenylethyl)-3-p-tolyloxaziridineC16H17NOEe = 100%[α]D21.3=-55.0 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-2-(1-Phenylethyl)-3-p-tolyloxaziridineC16H17NOEe = 100%[α]D21.3=+60.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-2-(1-Phenylethyl)-3-p-tolyloxaziridineC16H17NOEe = 100%[α]D21.3=+56.7 (c 0.03, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-2-(1-Phenylethyl)-3-p-tolyloxaziridineC16H17NOEe = 100%[α]D21.3=-61.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridineC16H17NO2Ee = 100%[α]D25.0=-41.9 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridineC16H17NO2Ee = 100%[α]D25.0=+90.6 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridineC16H17NO2Ee = 100%[α]D25.0=+43.0 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-3-(4-Methoxyphenyl)-2-(1-phenylethyl)oxaziridineC16H17NO2Ee = 100%[α]D25.0=-89.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridineC15H14ClNOEe = 100%[α]D22.1=-44.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridineC15H14ClNOEe = 100%[α]D22.1=+97.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridineC15H14ClNOEe = 100%[α]D22.1=+44.6 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-3-(4-Chlorophenyl)-2-(1-phenylethyl)oxaziridineC15H14ClNOEe = 100%[α]D22.1=-96.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D24.0=-78.1 (c 0.03, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D24.0=+91.8 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D24.0=+77.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D24.0=-92.2 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D22.3=-103.9 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D22.3=+37.4 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D22.3=+102.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-4-[2-(1-Phenylethyl)oxaziridin-3-yl]pyridineC14H14N2OEe = 100%[α]D22.3=-38.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazoleC13H14N2OSEe = 100%[α]D23.0=-60.2 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazoleC13H14N2OSEe = 100%[α]D23.0=+84.6 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazoleC13H14N2OSEe = 100%[α]D23.0=+58.8 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-4-Methyl-2-[2-(1-phenylethyl)oxaziridin-3-yl]thiazoleC13H14N2OSEe = 100%[α]D23.0=-84.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′S,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazoleC16H14N2OSEe = 100%[α]D21.0=-55.6 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2S,3S)
(+)-(1′S,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazoleC16H14N2OSEe = 100%[α]D21.0=+80.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,2R,3R)
(+)-(1′R,2R,3R)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazoleC16H14N2OSEe = 100%[α]D21.0=+56.0 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2R,3R)
(−)-(1′R,2S,3S)-2-[2-(1-Phenylethyl)oxaziridin-3-yl]benzothiazoleC16H14N2OSEe = 100%[α]D21.0=-80.7 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,2S,3S)
(−)-(1′R,3R,5R)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=-50.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3R,5R)
(+)-(1′R,3R,5S)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=+70.4 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3R,5S)
(+)-(1′S,3S,5S)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=+50.0 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3S,5S)
(−)-(1′S,3S,5R)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=-70.2 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3S,5R)
(+)-(1′R,3S,5S)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=+21.2 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3S,5S)
(−)-(1′R,3S,5R)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=-26.0 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3S,5R)
(−)-(1′S,3R,5R)-(trans)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=-21.0 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3R,5R)
(+)-(1′S,3R,5S)-(cis)-2-[3-Phenyl-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC22H22N2OEe = 100%[α]D24.0=+26.3 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3R,5S)
(−)-(1′R,3R,5R)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=-55.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3R,5R)
(−)-(1′S,3S,5R)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=-65.6 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3S,5R)
(+)-(1′S,3S,5S)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=+55.1 (c 0.02, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3S,5S)
(+)-(1′R,3R,5S)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0 = +64.9 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3R,5S)
(−)-(1′S,3R,5R)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=-15.1 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3R,5R)
(+)-(1′S,3R,5S)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=+30.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′S,3R,5S)
(+)-(1′R,3S,5S)-(trans)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=+15.5 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3S,5S)
(−)-(1′R,3S,5R)-(cis)-2-[3-(4-Methoxyphenyl)-2-(1-phenylethyl)isoxazolidin-5-yl]pyridineC23H24N2O2Ee = 100%[α]D21.0=-31.3 (c 0.01, CHCl3)Source of chirality: asymmetric inductionAbsolute configuration: (1′R,3S,5R)
